Skip to Content

Infanrix Penta

Active Substance: diphtheria toxoid / tetanus toxoid / Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) / hepatitis-B surface antigen / poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain))
Common Name: diphtheria, tetanus, pertussis (acellular, component), hepatitis-B (rDNA) and poliomyelitis (inactivated) vaccine (adsorbed)
ATC Code: J07CA12
Marketing Authorisation Holder: GlaxoSmithKline Biologicals S.A.
Active Substance: diphtheria toxoid / tetanus toxoid / Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin) / hepatitis-B surface antigen / poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain))
Status: Withdrawn
Authorisation Date: 2000-10-23
Therapeutic Area: Hepatitis B Diphtheria Poliomyelitis Whooping Cough Immunization Tetanus
Pharmacotherapeutic Group: Vaccines

Therapeutic Indication

Infanrix Penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B and poliomyelitis.

This marketing authorisation for Infanrix Penta has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide